Comparative Risk of Cerebrovascular Adverse Events in Community-Dwelling Older Adults using Risperidone, Olanzapine and Quetiapine
- 246 Downloads
Atypical antipsychotic agents have been associated with cerebrovascular adverse events, particularly in elderly dementia patients. However, limited evidence exists regarding comparative cerebrovascular profiles of individual atypical agents, particularly in community settings.
The objective of this study was to evaluate the risk of cerebrovascular events associated with use of risperidone, olanzapine and quetiapine in community-dwelling older adults in the US.
A propensity score-adjusted retrospective cohort design involving the IMS LifeLink™ Health Plan Claims Database was used for the study. The study population included all older adults (aged ≥50 years) who initiated risperidone, olanzapine or quetiapine anytime during 1 July 2000 to 30 June 2008. Patients were followed until hospitalization or an emergency room visit for a cerebrovascular event, or the end of the study period, whichever occurred earlier. The Cox proportional hazard regression model with time-varying covariates was used to evaluate the risk of cerebrovascular events during the follow-up period, using olanzapine as the reference. The covariates adjusted for in the final model included multiple propensity scores and exposure to other medications that could be associated with the risk of cerebrovascular events.
A total of 2,458 cerebrovascular events were identified in the study cohort: 1,081 (21.38 %) for risperidone users, 816 (18.75 %) for olanzapine users and 561 (21.05 %) for quetiapine users. After adjusting for propensity scores and other covariates, the Cox proportional hazard model revealed that use of quetiapine [hazard ratio (HR) 0.88; 95 % CI 0.78, 0.99] but not risperidone (HR 1.05; 95 % CI 0.95, 1.16) was associated with a decrease in the risk of cerebrovascular adverse events compared with olanzapine.
The study suggested that quetiapine use may be associated with a moderately lower risk of cerebrovascular events than olanzapine in older adults. Prescribers should closely monitor the patients treated with atypical agents for the incidence of cerebrovascular adverse events.
The statements, findings, conclusions, views and opinions contained and expressed in this article are based in part on data obtained under license from the IMS LifeLink™ Health Plan Claims Database (1999–2003), IMS Health Incorporated. All rights reserved. The statements, findings, conclusions, views and opinions contained and expressed herein are not necessarily those of IMS Health Incorporated or any of its affiliated or subsidiary entities. The authors have no conflicts of interest to disclose that are directly relevant to the content of this study. No sources of funding were received to conduct this study.
- 2.Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1):CD003476.Google Scholar
- 8.Kleijer BC, van Marum RJ, Egberts AC, Jansen PA, Knol W, Heerdink ER. Risk of cerebrovascular events in elderly users of antipsychotics. J Psychopharmacol. 2009;23(8):909–14.Google Scholar
- 14.Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry. 2000;57(10):968–76.PubMedCrossRefGoogle Scholar
- 19.Layton D, Harris S, Wilton LV, Shakir SAW. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia. J Psychopharmacol. 2005;19(5):473–82.PubMedCrossRefGoogle Scholar
- 25.Agency for Healthcare Research and Quality Center for Cost and Financing Studies. MEPS HC-052. 2000 medical conditions. June 2003. http://www.meps.ahrq.gov/mepsweb/data_stats/download_data/pufs/h52/h52doc.pdf. Accessed 2009 Apr 16.
- 34.McFadden D, Train K, Tye W. An application of diagnostic tests for the independence from irrelevant alternatives property of the multinomial logit model. Transp Res Rec. 1976;637:39–45.Google Scholar
- 36.Gottlieb S. Warnings issued over COX 2 inhibitors in US and UK. BMJ. 2005;330(9):4.Google Scholar
- 40.Greenspan A, Eerdekens M, Mahmoud R. Is there an increased risk of cerebrovascular adverse events among dementia patients treated with risperidone? In: Proceedings of the annual meeting of the International College of Geriatric Psychoneuropharmacology, San Juan, 12–14 Dec 2003.Google Scholar
- 41.Greenspan A, Eerdekens M, Mahmoud R. Is there an increased rate of cerebrovascular adverse events with risperidone in patients with dementia? [abstract]. Int J Neuropsychopharmacol. 2004;7(Suppl. 1):S205.Google Scholar
- 45.Perkins DO. Antipsychotic-induced hyperprolactinemia: pathophysiology and clinical consequences. Adv Stud Med. 2004;4(10F):S982–6.Google Scholar